Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Brazil: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Brazil: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in Brazil?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Brazil Patent PI0722383

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Brazil?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Brazil Patent PI0815979

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can PICATO (ingenol mebutate) generic drug versions launch in Brazil?

Generic name: ingenol mebutate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 18, 2026
Generic Entry Controlled by: Brazil Patent PI0619919
Patent Title: composições terapêuticas

Drug Price Trends for PICATO
PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. Additional details are available on the ingenol mebutate profile page.

When can EPSOLAY (benzoyl peroxide) generic drug versions launch in Brazil?

Generic name: benzoyl peroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Brazil Patent PI0808160

Drug Price Trends for EPSOLAY
EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. Additional details are available on the benzoyl peroxide profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Brazil?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Brazil Patent PI0807453

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Brazil?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Brazil Patent PI0807718

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Brazil?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Brazil Patent PI0807718

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can DYANAVEL XR (amphetamine) generic drug versions launch in Brazil?

Generic name: amphetamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: Brazil Patent PI0709606
Patent Title: suspensão líquida administrável oralmente com características de liberação modificada

Drug Price Trends for DYANAVEL XR
DYANAVEL XR is a drug marketed by Tris Pharma Inc. There are twelve patents protecting this drug. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering DYANAVEL XR

See drug price trends for DYANAVEL XR.

The generic ingredient in DYANAVEL XR is amphetamine. Additional details are available on the amphetamine profile page.

When can TUZISTRA XR (chlorpheniramine polistirex; codeine polistirex) generic drug versions launch in Brazil?

Generic name: chlorpheniramine polistirex; codeine polistirex
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 15, 2027
Generic Entry Controlled by: Brazil Patent PI0709606
Patent Title: suspensão líquida administrável oralmente com características de liberação modificada

TUZISTRA XR is a drug marketed by Tris Pharma Inc. There are two patents protecting this drug. There has been litigation on patents covering TUZISTRA XR

See drug price trends for TUZISTRA XR.

The generic ingredient in TUZISTRA XR is chlorpheniramine polistirex; codeine polistirex. Additional details are available on the chlorpheniramine polistirex; codeine polistirex profile page.

When can XENLETA (lefamulin acetate) generic drug versions launch in Brazil?

Generic name: lefamulin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 20, 2027
Generic Entry Controlled by: Brazil Patent PI0809023

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Brazil?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Brazil Patent PI0809522
Patent Title: COMPOSIÇÃO FARMACÊUTICA SÓLIDA, MÉTODOS PARA ESTABILIZAR UM COMPOSTO, E PARA MELHORAR DISSOLUÇÃO DE UM COMPOSTO, E, USO DE UM AGENTE DE CONTROLE DE PH.

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can INLYTA (axitinib) generic drug versions launch in Brazil?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Brazil Patent PI0809471

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can SYMDEKO (COPACKAGED) (ivacaftor; ivacaftor, tezacaftor) generic drug versions launch in Brazil?

Generic name: ivacaftor; ivacaftor, tezacaftor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 09, 2027
Generic Entry Controlled by: Brazil Patent PI0710965
Patent Title: moduladores de transportadores de cassete de ligação de atp

SYMDEKO (COPACKAGED) is a drug marketed by Vertex Pharms Inc. There are twenty-six patents protecting this drug. There has been litigation on patents covering SYMDEKO (COPACKAGED)

The generic ingredient in SYMDEKO (COPACKAGED) is ivacaftor; ivacaftor, tezacaftor. Additional details are available on the ivacaftor; ivacaftor, tezacaftor profile page.

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch in Brazil?

Generic name: beclomethasone dipropionate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: Brazil Patent PI0809477

Drug Price Trends for QVAR REDIHALER
QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. Additional details are available on the beclomethasone dipropionate profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Brazil?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Brazil Patent PI0721651

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can ICLUSIG (ponatinib hydrochloride) generic drug versions launch in Brazil?

Generic name: ponatinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 08, 2027
Generic Entry Controlled by: Brazil Patent PI0710331

ICLUSIG is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering ICLUSIG

See drug price trends for ICLUSIG.

The generic ingredient in ICLUSIG is ponatinib hydrochloride. Additional details are available on the ponatinib hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Brazil?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Brazil Patent PI0811199

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Brazil?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Brazil Patent PI0811904

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can TRELSTAR (triptorelin pamoate) generic drug versions launch in Brazil?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Brazil Patent PI0812250

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can TRIPTODUR KIT (triptorelin pamoate) generic drug versions launch in Brazil?

Generic name: triptorelin pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2027
Generic Entry Controlled by: Brazil Patent PI0812250

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. Additional details are available on the triptorelin pamoate profile page.

When can XADAGO (safinamide mesylate) generic drug versions launch in Brazil?

Generic name: safinamide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2027
Generic Entry Controlled by: Brazil Patent PI0712936

Drug Price Trends for XADAGO
XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. Additional details are available on the safinamide mesylate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in Brazil?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: Brazil Patent PI0814254

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch in Brazil?

Generic name: remimazolam besylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2027
Generic Entry Controlled by: Brazil Patent PI0714886
Patent Title: sais de benzodiazepina de aÇço rÁpida e suas formas polimàrficas

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. Additional details are available on the remimazolam besylate profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Brazil?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Brazil Patent PI0813707
Patent Title: DERIVADOS DE PIRIMIDINIL-PIRIDAZINONA

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Brazil?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Brazil Patent PI0814299

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can RASUVO (methotrexate) generic drug versions launch in Brazil?

Generic name: methotrexate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 20, 2027
Generic Entry Controlled by: Brazil Patent PI0715433

Drug Price Trends for RASUVO
RASUVO is a drug marketed by Medexus. There is one patent protecting this drug. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. Additional details are available on the methotrexate profile page.

When can WINLEVI (clascoterone) generic drug versions launch in Brazil?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: Brazil Patent PI0814163
Patent Title: PROCESSO PARA A PREPARAÇÃO DE COMPOSTOS, FORMA CRISTALINA, E, COMPOSIÇÃO FARMACÊUTICA

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Brazil?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 20, 2027
Generic Entry Controlled by: Brazil Patent PI0715712

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can KORSUVA (difelikefalin acetate) generic drug versions launch in Brazil?

Generic name: difelikefalin acetate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 12, 2027
Generic Entry Controlled by: Brazil Patent PI0718651

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. Additional details are available on the difelikefalin acetate profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Brazil?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Brazil Patent PI0820308
Patent Title: Composições farmacêuticas

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Brazil?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Brazil Patent PI0720264

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Brazil?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 20, 2027
Generic Entry Controlled by: Brazil Patent PI0722384

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Brazil?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Brazil Patent PI0819319
Patent Title: Análogos de aminoglicosídeo antibacteriano

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Brazil?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Brazil Patent PI0819847

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Brazil?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Brazil Patent PI0918584

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Brazil?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Brazil Patent PI0918586

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Brazil?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Brazil Patent PI0819847

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Brazil?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Brazil Patent PI0918584

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Brazil?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Brazil Patent PI0918586

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Brazil?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 03, 2027
Generic Entry Controlled by: Brazil Patent PI0719693

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Brazil?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2027
Generic Entry Controlled by: Brazil Patent PI0720178
Patent Title: DERIVADOS DE 2,3-DI-HIDROIMIDAZO[1,2-C]QUINAZOLINA SUBSTITUÍDA ÚTEIS PARA TRATAR DISTÚRBIOS E DOENÇAS HIPERPROLIFERATIVOS ASSOCIADOS COM ANGIOGÊNESE

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Brazil?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 11, 2027
Generic Entry Controlled by: Brazil Patent PI0720270

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can INVEGA SUSTENNA (paliperidone palmitate) generic drug versions launch in Brazil?

Generic name: paliperidone palmitate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 19, 2027
Generic Entry Controlled by: Brazil Patent PI0821408

Drug Price Trends for INVEGA SUSTENNA
INVEGA SUSTENNA is a drug marketed by Janssen Pharms. There is one patent protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market. There has been litigation on patents covering INVEGA SUSTENNA

See drug price trends for INVEGA SUSTENNA.

The generic ingredient in INVEGA SUSTENNA is paliperidone palmitate. Additional details are available on the paliperidone palmitate profile page.

When can SOLUPREP (chlorhexidine gluconate; isopropyl alcohol) generic drug versions launch in Brazil?

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 31, 2027
Generic Entry Controlled by: Brazil Patent PI0819567
Patent Title: "composições antimicrobianas, método para aprimorar a adesão molhada do artigo adesivo médico e método para evitar ou tratar uma condição da pele de um mamífero

SOLUPREP is a drug marketed by Solventum.

The generic ingredient in SOLUPREP is chlorhexidine gluconate; isopropyl alcohol. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Brazil Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks, and Market Entry

Last updated: October 14, 2026

Brazil is Latin America’s largest pharmaceutical market and combines strong demand growth with intensive price regulation, complex federal procurement, local manufacturing requirements, and a fragmented commercial structure. Branded products retain value through physician preference, hospital relationships, formulation differentiation, and public-sector access. Generics and similar medicines compete aggressively on price and distribution.

The main opportunities are Brazil’s large patient base, expansion of private healthcare, rising chronic-disease treatment, public procurement, biosimilar adoption, and local production incentives. The main risks are CMED price controls, lengthy regulatory review, patent uncertainty, exchange-rate exposure, tax complexity, and state-level procurement fragmentation.

How large is Brazil’s branded and generic drug market?

Brazil has a population exceeding 200 million and a pharmaceutical market supported by both the public Unified Health System, or SUS, and private healthcare. Demand is concentrated in chronic diseases, oncology, diabetes, cardiovascular conditions, central nervous system disorders, vaccines, hospital products, and specialty medicines.

Brazil’s market has four commercially relevant product categories:

Category Regulatory position Commercial characteristics
Reference medicine Original product approved with a complete dossier Usually has the strongest physician recognition and may support premium pricing
Generic medicine Must demonstrate pharmaceutical equivalence and bioequivalence to the reference product Uses the active ingredient name and is marketed with the “Genérico” designation
Similar medicine Similar composition and therapeutic indication to a reference medicine May become interchangeable after meeting ANVISA requirements
Biosimilar or similar biological product Regulated through biological-product pathways Requires analytical, clinical, and comparability evidence

Generics have become a structural part of Brazilian retail pharmacy. Large domestic companies compete with multinational manufacturers through broad distribution, pharmacy chains, private-label products, and government tenders. Branded generics also occupy a significant position because they combine manufacturer recognition with lower prices than reference medicines.

Public-sector purchasing is material but price-sensitive. SUS procurement, state tenders, municipal tenders, hospital contracts, and judicial health orders create separate demand channels. A product can have strong private-market sales but limited public-sector access if its price, reimbursement status, or tender economics are unfavorable.

What is the regulatory structure for drugs in Brazil?

The National Health Surveillance Agency, ANVISA, is responsible for drug registration, manufacturing authorization, inspections, pharmacovigilance, clinical-trial regulation, and post-market controls. The Ministry of Health and state and municipal health authorities also influence market access.

The principal regulatory framework includes:

  • Law No. 6,360/1976, which governs health products and medicines.
  • Law No. 9,787/1999, which created the Brazilian generic-drug framework.
  • Law No. 9,279/1996, Brazil’s Industrial Property Law.
  • Law No. 10,742/2003, which established the pharmaceutical price-regulation system.
  • RDC No. 753/2022, which consolidated rules for the registration of synthetic and semi-synthetic medicines.
  • RDC No. 55/2010, which governs biological products and biosimilars.
  • RDC No. 200/2017, which addresses registration of medicines and related regulatory requirements.

ANVISA requires Brazilian marketing authorization holders to maintain a local legal presence or use an authorized Brazilian representative. Manufacturing sites can be located abroad, but they remain subject to ANVISA inspection, recognized inspection evidence, or other applicable compliance mechanisms.

How does Brazil regulate generic drugs?

A generic medicine must demonstrate pharmaceutical equivalence and bioequivalence against the reference medicine designated by ANVISA. The product must generally have the same active ingredient, strength, dosage form, route of administration, and therapeutic indication, subject to applicable regulatory rules.

Brazilian generics are identified by the active pharmaceutical ingredient rather than a proprietary brand. The generic label also carries the “Genérico” designation. Registration does not automatically guarantee substitution in every setting. Pharmacy substitution, prescriber instructions, institutional protocols, and procurement rules can affect actual interchangeability.

How does Brazil regulate similar medicines?

Similar medicines can be marketed under a brand name. A similar product may obtain an interchangeable status after satisfying ANVISA’s requirements, which can include bioequivalence, pharmaceutical equivalence, or other evidence depending on the product and regulatory pathway.

This creates a competitive category between reference medicines and generics. A company with manufacturing capability, distribution reach, and physician access can compete through branded similars even when it does not own the original molecule.

How does Brazil’s drug pricing system work?

The Câmara de Regulação do Mercado de Medicamentos, or CMED, regulates pharmaceutical pricing. CMED establishes maximum prices through the following principal concepts:

  • Factory price.
  • Maximum consumer price.
  • Maximum government selling price.
  • Price adjustments based on regulatory formulas.
  • Reference pricing and therapeutic-class comparisons for new products.

A new medicine typically cannot be priced solely on the basis of development cost or foreign launch price. The pricing pathway depends on the product’s innovation category, therapeutic comparator, clinical benefit, and international reference prices.

Price regulation creates several commercial effects:

  1. A first generic or similar entrant may gain volume but face limited gross-margin expansion.
  2. Government procurement can require discounts materially below the listed private-market price.
  3. Products with differentiated clinical value may receive a better pricing position than products entering crowded therapeutic classes.
  4. Foreign exchange movements can pressure margins when active pharmaceutical ingredients are imported.
  5. Taxes and distribution costs vary by state, complicating national net-price analysis.

Companies entering Brazil should model factory price, wholesaler discounts, pharmacy discounts, tender discounts, taxes, chargebacks, and inventory financing separately. A listed maximum price is not a reliable proxy for net realized revenue.

What patents protect branded drugs in Brazil?

Brazil grants pharmaceutical patents under the Industrial Property Law, subject to novelty, inventive step, industrial application, and statutory exclusions. A standard patent generally expires 20 years from the filing date. Brazilian law also provides a minimum term of 10 years from grant for invention patents and seven years from grant for utility models, subject to statutory provisions.

The patent estate for a branded medicine can include:

  • Composition-of-matter patents.
  • Polymorph, salt, crystal, and stereoisomer patents.
  • Formulation and dosage-form patents.
  • Controlled-release or extended-release patents.
  • Combination-treatment patents.
  • Manufacturing-process patents.
  • Method-of-use patents.
  • Device or drug-delivery patents.
  • Pediatric, oncology, or patient-subgroup claims.

Brazil does not provide the same broad patent-term-extension structure found in the United States. Patent-delay analysis is therefore important. A long prosecution period may preserve the 10-year post-grant floor, but it does not generally create a separate period equivalent to U.S. patent-term adjustment or European supplementary protection certificates.

Does Brazil have an Orange Book or patent linkage?

Brazil does not operate a U.S.-style Orange Book that links generic approval to listed patents. ANVISA generally evaluates regulatory requirements independently from patent validity and infringement.

There is no automatic requirement for a generic applicant to certify against all patents covering a reference product. Patent disputes are ordinarily handled through civil litigation rather than through a formal Paragraph IV certification system.

Brazil’s prior-consent requirement for pharmaceutical patent applications was removed by Law No. 14,195/2021. Patent examination is conducted by the Brazilian National Institute of Industrial Property, or INPI, under the current institutional framework.

When does a branded medicine lose exclusivity in Brazil?

Regulatory exclusivity and patent exclusivity must be analyzed separately.

For a small-molecule medicine, practical loss of exclusivity may occur when:

  • The active-ingredient patent expires.
  • A generic or similar product obtains approval.
  • A formulation patent is avoided or invalidated.
  • A method-of-use patent does not block the competing label.
  • Procurement or substitution rules favor lower-cost products.
  • Physicians shift prescribing before patent expiry.

Brazil does not generally provide broad human-pharmaceutical clinical data exclusivity comparable to the U.S. Hatch-Waxman framework. Law No. 10,603/2002 protects certain undisclosed test data, but its scope is not equivalent to a broad automatic exclusivity period for all human pharmaceutical products.

A generic applicant may conduct tests and studies needed for regulatory approval under the Bolar-type exception in Article 43, VII, of the Industrial Property Law. This permits preparatory regulatory work before patent expiry, although commercial manufacture and sale can still create infringement exposure.

What Paragraph IV challenges and generic launch risks exist in Brazil?

Brazil has no formal Paragraph IV process. The practical equivalent is a pre-launch or early-launch strategy based on one or more of the following positions:

  • The relevant patent has expired.
  • The patent is invalid for lack of novelty or inventive step.
  • The product does not fall within the patent claims.
  • The patent covers a nonessential formulation or use.
  • The generic label omits a patented indication.
  • The patent is unenforceable against the proposed product.
  • The applicant is relying on the Bolar exception for development only.

Launch scenarios normally fall into four groups:

Launch scenario Timing Principal risk
At-risk launch before all secondary patents expire Before full patent estate expiry Preliminary injunction, damages, inventory seizure, commercial disruption
Launch after composition patent expiry After core exclusivity ends Formulation, process, use, and device patents
Skinny-label or limited-indication launch After approval for non-patented uses Labeling, substitution, prescriber behavior, and induced-infringement allegations
Settlement-controlled launch Based on negotiated date and conditions Enforceability, competition-law scrutiny, and later patent challenges

The absence of patent linkage can accelerate regulatory entry, but it does not remove litigation risk. A company can obtain a marketing authorization and still face an injunction or damages action.

How strong are patent estates for branded drugs in Brazil?

Patent strength depends less on the number of filings than on claim scope, validity, enforceability, and the ability to identify an infringing product.

A strong estate typically has:

  • A valid composition patent with meaningful remaining term.
  • Claims that cover the commercial dosage form.
  • Manufacturing claims that are difficult to design around.
  • A formulation patent linked to the actual marketed product.
  • Method-of-use claims aligned with the approved indication.
  • Consistent prosecution positions across Brazil and major jurisdictions.
  • Evidence supporting inventive step and unexpected technical effect.

A weaker estate often depends on late-filed secondary patents, narrow polymorph claims, broad method-of-treatment claims, or patents that do not cover the generic’s proposed label.

Brazilian patent litigation can involve federal courts, state courts, technical expert evidence, validity challenges before INPI, and appeals. Litigation timing varies by court and case posture. Preliminary relief can determine market access before a final validity decision.

What patent litigation and settlement issues affect Brazil?

Patent holders may seek preliminary injunctions to block manufacture, importation, distribution, or sale. Generic manufacturers can challenge patents through infringement defenses, invalidity arguments, non-infringement positions, and administrative or judicial actions involving INPI.

Settlement agreements may address:

  • Agreed generic launch dates.
  • Limited indications or restricted labels.
  • Supply or licensing arrangements.
  • Waivers of damages.
  • Non-challenge provisions.
  • Manufacturing and distribution terms.

Settlement terms must be assessed under Brazilian competition law. The Administrative Council for Economic Defense, or CADE, can review conduct that delays generic entry or allocates markets. A settlement that restricts entry beyond the enforceable patent scope can create competition-law risk.

What biosimilar opportunities and risks exist in Brazil?

Brazil regulates biological products through reference biological products, biosimilars, and other biological pathways. Biosimilar development requires analytical comparability and a clinical package proportionate to the product and regulatory pathway.

The commercial opportunity is strongest in high-cost categories such as oncology, immunology, endocrinology, and hospital biologics. Public procurement is often decisive because SUS purchasing can rapidly shift volume toward lower-cost biological products.

Biosimilar risks include:

  • Complex manufacturing validation.
  • Cold-chain requirements.
  • Limited interchangeability certainty.
  • Physician and hospital reluctance to switch patients.
  • Procurement concentration.
  • Immunogenicity and pharmacovigilance obligations.
  • Patent claims covering formulations, dosing, manufacturing, and indications.

Brazil’s biosimilar market should not be analyzed using small-molecule generic assumptions. Approval does not necessarily produce automatic pharmacy substitution or rapid reference-product erosion.

What regulatory opportunities exist for pharmaceutical companies?

The most significant opportunities are:

Local manufacturing and technology transfer

The government supports domestic production through public-private partnerships, technology-transfer arrangements, local-content programs, and procurement policies. These structures can improve access to SUS tenders and reduce import dependence.

Government procurement and SUS access

Companies with products on public formularies, strategic-medicine lists, or centralized procurement programs can access large institutional volumes. The trade-off is lower pricing and more demanding supply obligations.

Specialty and hospital medicines

Complex generics, injectables, oncology products, biosimilars, and hospital medicines can face less retail fragmentation than conventional oral solids. Manufacturing and quality barriers also reduce the number of credible competitors.

Contract manufacturing and licensing

Foreign companies can enter through local licensing, contract manufacturing, distribution, co-promotion, or technology transfer instead of building a full Brazilian commercial organization. Agreements should allocate ANVISA responsibility, pharmacovigilance, recalls, supply continuity, price filings, patent enforcement, and tender participation.

Regulatory reliance and accelerated review

ANVISA has used reliance mechanisms and priority pathways for certain products, including public-health priorities and innovative therapies. Eligibility depends on the product category and current ANVISA rules. Reliance can shorten review time but does not eliminate local dossier, GMP, pharmacovigilance, or pricing obligations.

What are the main regulatory and commercial challenges?

The principal obstacles are:

Challenge Business impact
ANVISA review and technical requirements Delayed launch and higher registration cost
CMED price regulation Limits pricing flexibility
Imported API dependence Exposure to currency, logistics, and geopolitical disruption
Tax complexity Different net economics by state and channel
Tender concentration Volume volatility and margin pressure
Patent uncertainty Potential injunctions after regulatory approval
Local representation requirements Need for qualified Brazilian infrastructure
GMP and pharmacovigilance obligations Ongoing compliance cost
Judicial health orders Unpredictable demand and reimbursement exposure
Distribution fragmentation Higher working capital and channel-management costs

Brazil also creates execution risk through federal, state, and municipal decision-making. A national launch plan that ignores regional tender practices, tax treatment, distributor structure, and local prescribing behavior can overestimate revenue.

How does Brazil compare with the United States and Europe?

Issue Brazil United States European Union
Generic patent linkage No Orange Book-style linkage FDA Orange Book and certification system National and EU-level mechanisms vary
Small-molecule data exclusivity Limited compared with U.S. framework Hatch-Waxman exclusivity periods EU data and market exclusivity framework
Price controls CMED regulates maximum prices Generally no national maximum retail price National reimbursement and price controls
Patent term Generally 20 years from filing, with statutory grant-term rules 20 years plus possible adjustments 20 years, with possible supplementary protection
Biosimilar substitution Depends on product and local practice State and federal rules Member-state implementation varies
Public procurement SUS and decentralized tenders Federal and private purchasing National health systems and tenders

Brazil can offer faster commercial entry after core patent expiry than a linkage-heavy system, but regulatory approval does not provide a safe harbor against patent litigation.

What market-entry strategy is most defensible?

A defensible Brazil strategy requires parallel regulatory, patent, pricing, and supply-chain workstreams:

  1. Identify the ANVISA reference product and applicable registration pathway.
  2. Map composition, formulation, process, use, device, and manufacturing patents.
  3. Review INPI prosecution history and remaining patent term.
  4. Assess Bolar activity and the earliest defensible commercial-launch date.
  5. Model CMED pricing and tender discounts.
  6. Select local licensing, distribution, or manufacturing partners.
  7. Establish pharmacovigilance, recall, and supply-continuity controls.
  8. Segment private retail, hospitals, SUS, and specialty channels.
  9. Evaluate biosimilar interchangeability and procurement behavior separately.
  10. Prepare litigation and injunction scenarios before regulatory filing.

Key Takeaways

  • Brazil is a large, regulated pharmaceutical market with strong demand for generics, branded similars, complex products, and biosimilars.
  • ANVISA approval is separate from patent clearance; Brazil has no U.S.-style Orange Book or formal Paragraph IV process.
  • CMED pricing can materially reduce the value of regulatory approval and must be modeled at net realized price.
  • Core composition patents, formulation patents, use patents, and manufacturing patents require separate analysis.
  • The Bolar exception supports pre-expiry regulatory development but does not authorize commercial launch.
  • SUS procurement offers significant volume but increases price, supply, and compliance pressure.
  • Local manufacturing, licensing, and technology transfer can improve public-sector access.
  • Biosimilar opportunities are substantial, but interchangeability, procurement, and manufacturing risks remain high.
  • Patent settlements should be reviewed for both enforceability and Brazilian competition-law exposure.
  • The strongest entry plans integrate ANVISA, INPI, CMED, litigation, procurement, and supply-chain analysis.

FAQs About Brazil’s Branded and Generic Drug Market

Does Brazil require a generic drug to have the same active ingredient as the reference product?

Yes. A generic generally must contain the same active ingredient and meet applicable requirements for pharmaceutical equivalence, bioequivalence, dosage form, strength, route, and therapeutic indication.

Can a generic launch in Brazil before the branded medicine’s patent expires?

Regulatory development and testing can occur under the Bolar-type exception. Commercial manufacture, importation, distribution, or sale before enforceable patent expiry can create infringement risk.

Does Brazil grant pharmaceutical data exclusivity for human medicines?

Brazil does not generally provide a broad human-pharmaceutical data-exclusivity regime equivalent to the principal U.S. Hatch-Waxman periods. Protection under Law No. 10,603/2002 has a narrower statutory scope.

Are biosimilars automatically interchangeable with reference biologics in Brazil?

No. Interchangeability depends on the applicable ANVISA requirements, product classification, clinical evidence, prescriber decisions, and institutional or procurement practice.

Can a foreign pharmaceutical company sell medicines in Brazil without a Brazilian entity?

A foreign company normally must operate through a qualified Brazilian marketing authorization holder, local representative, distributor, or other structure that satisfies ANVISA and commercial requirements.

References

  1. Agência Nacional de Vigilância Sanitária. (2010). RDC No. 55, of December 16, 2010: Registration of biological products. ANVISA.

  2. Agência Nacional de Vigilância Sanitária. (2017). RDC No. 200, of December 26, 2017: Criteria for the granting, renewal, alteration, inclusion, suspension, and cancellation of marketing authorization for medicines. ANVISA.

  3. Agência Nacional de Vigilância Sanitária. (2022). RDC No. 753, of September 28, 2022: Registration of synthetic and semi-synthetic medicines. ANVISA.

  4. Brazil. (1976). Law No. 6,360, of September 23, 1976: Health surveillance of medicines and related products.

  5. Brazil. (1996). Law No. 9,279, of May 14, 1996: Industrial property law.

  6. Brazil. (1999). Law No. 9,787, of February 10, 1999: Generic medicines law.

  7. Brazil. (2002). Law No. 10,603, of December 17, 2002: Protection of undisclosed information submitted to public authorities.

  8. Brazil. (2003). Law No. 10,742, of October 6, 2003: Pharmaceutical price regulation and CMED.

  9. Brazil. (2021). Law No. 14,195, of August 26, 2021: Business environment and industrial property provisions.

  10. Câmara de Regulação do Mercado de Medicamentos. (2024). Pharmaceutical price-regulation rules and price-adjustment framework. CMED.

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.